We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Histone Deacetylase Inhibitor, Trichostatin A, Synergistically Enhances Paclitaxel-Induced Cytotoxicity in Urothelial Carcinoma Cells by Suppressing the ERK Pathway.
- Authors
Hsu, Fu-Shun; Wu, June-Tai; Lin, Jing-Yi; Yang, Shao-Ping; Kuo, Kuan-Lin; Lin, Wei-Chou; Shi, Chung-Sheng; Chow, Po-Ming; Liao, Shih-Ming; Pan, Chun-I; Hong, Jo-Yu; Chang, Hong-Chiang; Huang, Kuo-How
- Abstract
Trichostatin A (TSA), an antifungal antibiotic derived from Streptomyces, inhibits mammalian histone deacetylases, and especially, selectively inhibits class I and II histone deacetylase (HDAC) families of enzymes. TSA reportedly elicits an antiproliferative response in multifarious tumors. This study investigated the antitumor effects of TSA alone and in combination with paclitaxel when applied to two high-grade urothelial carcinoma (UC) cell lines (BFTC-905 and BFTC-909). Fluorescence-activated cell sorting, flow cytometry, and 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium assay were used to assess TSA's cytotoxicity and effects on apoptosis induction. TSA induced synergistic cytotoxicity, when combined with paclitaxel (combination index < 1), resulted in concomitant suppression of paclitaxel-induced activation of phospho-extracellular signal-regulated kinase (ERK) 1/2. A xenograft nude mouse model confirmed that TSA enhances the antitumor effects of paclitaxel. These findings demonstrate that the administration of TSA in combination with paclitaxel elicits a synergistic cytotoxic response. The results of this study indicate that the chemoresistance of UC could be circumvented by combining HDAC inhibitors to target the ERK pathway.
- Subjects
DEACETYLASES; CANCER cells; CELL lines; TRICHOSTATIN A; PACLITAXEL
- Publication
International Journal of Molecular Sciences, 2019, Vol 20, Issue 5, p1162
- ISSN
1661-6596
- Publication type
Article
- DOI
10.3390/ijms20051162